Neuromodulation Devices Global Market- Forecast to 2029

Publishing Date : March, 2023
Report Code : HCMD0131
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Neuromodulation is the alteration of nerve activity through the delivery of an electric and magnetic stimulus. Applications for neuromodulation include therapies for a wide range of disorders, as well as a tool for medical and neuroscientific research. It is used as a treatment for unmanageable chronic pain, movement disorders, neurological diseases, gastroenterology, respiratory related diseases and others. The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches. This therapy is based on the natural process of stimulation of nerve cell activity and release of neurotransmitters that regulate nerve activity. Neuromodulation is gaining popularity because these devices have been very successful in the treatment of conditions for which medicines have failed completely or may have unpleasant side effects.

According to IQ4I analysis, the neuromodulation devices global market is expected to reach $9,427.7 million by 2029 growing at a high single digit CAGR from 2022 to 2029. The factors such as increasing prevalence of chronic pain conditions, central nervous system disorders such as Parkinson disease, Alzheimer disease, Multiple sclerosis, Epilepsy and others (According to U.S. Parkinson’s U.S. foundation, nearly one million people in the U.S. are living with Parkinson's disease (PD) and this number is expected to rise to 1.2 million by 2030. The prevalence of Parkinson’s in the U.K. is a total of about 127,000 people living with the disease, The prevalence of epilepsy is estimated to be 5.0 million people in U.S. in 2022), low approval rate of CNS drugs and favorable reimbursement scenario in major markets are driving the neuromodulation market. The emergence of neuromodulation as add-on therapy, technological innovations in neuromodulation, expansion in emerging markets and the rise in the number of clinical studies performed provides immense opportunities to the neuromodulation market. However, side effects and risks associated with the use, lack of trained professionals, availability of alternative treatments and stringent regulatory guidelines are expected to hamper the market growth.

The neuromodulation global market is segment based on product, application, end – users and geography. Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices. Among these, invasive neuromodulation devices segment accounted for the largest revenue in 2022 and is expected grow at a high single digit CAGR from 2022 to 2029. Invasive neuromodulation segment is further segmented into Spinal Cord Stimulator (SCS), Deep Brain Stimulator (DBS), Sacral Nerve Stimulator (SNS), Vagus Nerve Stimulator (VNS), Hypoglossal Nerve Stimulator (HGNS) and others.  Among invasive neuromodulation devices, Spinal cord stimulator (SCS) segment accounted for the largest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Hypoglossal Nerve Stimulator segment is the fastest growing segment with the revenue of $XX million in 2022 and is expected grow at a high double digit CAGR from 2022 to 2029.  The non-invasive neuromodulation devices market is segmented into Transcutaneous Electrical Nerve Stimulation (TENS), Neuromuscular Electrical Stimulation (NMES) and others. Among non-invasive neuromodulation devices, Transcutaneous Electrical Nerve Stimulator (TENS) segment is the largest and fastest growing segment with the revenue of $XX million in 2022 and is expected grow at a low single digit CAGR from 2022 to 2029.

Based on the application, the neuromodulation devices global market is segmented into Pain Management, Central Nervous System, Gastroenterology and Urology, Obstructive Sleep Apnea (OSA) and other. Among applications, pain management segment accounted for the largest revenue in 2022 and is grow at a mid single digit CAGR from 2022 to 2029. Obstructive Sleep Apnea segment is the fastest growing segment with the revenue of $XX million in 2022 and is expected to grow at a high double digit CAGR from 2022 to 2029.

Pain management is further segmented into chronic pain, failed back surgery syndrome (FBSS) and others. Among pain management, chronic pain segment is the largest and fastest growing segment accounted for the revenue of $XX million in 2022 and is expected to reach $XX million by 2029 growing at a mid single digit CAGR from 2022 to 2029. Central Nervous System is further segmented into Parkinson’s disease, Dystonia, Epilepsy and others include Obsessive Compulsive Disorder (OCD), Depression, Stroke, and Mood disorders, Anxiety, Central Sleep Apnea and Multiple Sclerosis. Among Central Nervous System disorders, Parkinson’s disease segment accounted for the largest revenue in 2022 and is expected grow at a CAGR mid single digit from 2022 to 2029. Epilepsy segment is the fastest growing segment with the revenue of $XX million in 2022 and is expected grow at a double digit CAGR from 2022 to 2029. Gastroenterology and Urology is further segmented into Gastroparesis, Urinary Incontinence and Faecal Incontinence. Among Gastroenterology and Urology, Urinary Incontinence segment accounted for the largest and fastest growing segment with the revenue of $XX million in 2022 and is expected to reach $XX million by 2029 growing at a mid single digit CAGR from 2022 to 2029.

Based on the end-user, the neuromodulation devices global market is segmented into Hospitals and Ambulatory Surgery Centers, Clinics and Physiotherapy Centers and Others include Home care, Academics and Research Institutes. Among end-user, Hospitals and Ambulatory Surgery Centers is the largest and fastest growing segment with the revenue of $XX million in 2022 and is expected grow at high single digit CAGR from 2022 to 2029.

Based on the region, the neuromodulation devices global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and Middle East & others). North America accounted for the largest revenue of $XX million in 2022 and is expected grow at a high single digit CAGR from 2022 to 2029. The factors such as increasing healthcare expenditure, increasing incidence of chronic pain problems, persistently increasing geriatric population with age related CNS disorders parkinson’s, alzheimer’s, epilepsy and incontinence problems, adoption of neurostimulation devices for the treatment of movement disorders, epilepsy, pain, and depression with rising number of approvals, increasing number of neuromodulation procedures and hospitals, presence of major players, launch of advanced neuromodulation devices by the companies, introduction of remote Neuromodulation Patient-Care Technology to increase the adoption, rising  funding for start-up companies for developing unique neuromodulation technologies and presence of dedicated non-profit organization devoted to the advancement of the field of neuromodulation are driving the neuromodulation market in the region.

Asia-Pacific is the fastest growing segment accounted for the revenue of $XX million in 2022 and is expected grow at a double digit CAGR from 2022 to 2029 The factors such as increasing healthcare expenditure, increasing aging population, increasing incidence and prevalence of targeted disease such as Chronic Pain, Parkinson’s disease, Alzheimer’s disease and incontinence problems, increasing adoption of implantable devices, high acceptance of technological advancements, government initiatives to increase awareness by education campaigns and development of neuromodulation devices and their approval in other markets boosts the growth of neuromodulation market in region.

The neuromodulation devices global market is a highly consolidated market hence all the existing players in this market are involved in developing new and advanced technologies to maintain their market shares. Some of the key players in neuromodulation devices global market include Medtronic Plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), LivaNova Plc (U.K.), Nevro Corporation (U.S.), Inspire Medical Technologies (U.S.), Bioventus (Bioness Inc) (U.S.), Neuropace Inc. (U.S.), Laborie Medical System Inc. (U.S.), Axonics Inc. (U.S.) and others

 

 

TABLE OF CONTENTS

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     Growing prevalence of treatment resistant chronic pain conditions
        • 3.3.1.2     Growing prevalence of central nervous system disorders such as parkinson disease, alzheimer disease, multiple sclerosis, epilepsy and others
        • 3.3.1.3     Low approval rate of CNS drugs
        • 3.3.1.4     Favorable reimbursement scenario in major markets
        • 3.3.1.5     The emergence of neuromodulation as add-on therapy
        • 3.3.1.6     Technological innovations in neuromodulation
        • 3.3.1.7     Expansion in emerging markets
        • 3.3.1.8     The rise in the number of clinical studies performed
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     Side effects and risks associated with the use
        • 3.3.2.2     Lack of trained professionals
        • 3.3.2.3     Availability of alternative treatments
        • 3.3.2.4     Stringent regulatory guidelines
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 13485 MEDICAL DEVICES
        • 3.4.1.3     ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     EUROPE
      • 3.4.5     JAPAN
      • 3.4.6     CHINA
      • 3.4.7     INDIA
    • 3.5     CLINICAL TRIALS DATA
    • 3.6     TECHNOLOGICAL ADVANCEMENTS
      • 3.6.1     RECHARGEABLE SYSTEMS
      • 3.6.2     FOCUSED ULTRASOUND (FUS)
      • 3.6.3     MINIATURIZATION
      • 3.6.4     PORTABLE NUEROMODULATION SYSTEMS (PONS)
      • 3.6.5     WEARABLE NEUROMODULATION TECHNOLOGY
      • 3.6.6     TRANS-SPINAL DIRECT CURRENT STIMULATION (TSDCS)
      • 3.6.7     NANO-NEUROMODULATION
      • 3.6.8     BIOACTIVE COATINGS
      • 3.6.9     TRANSCUTANEOUS VAGUS NERVE STIMULATION
    • 3.7     PORTER’S FIVE FORCE ANALYSIS
      • 3.7.1     THREAT OF NEW ENTRANTS
      • 3.7.2     THREAT OF SUBSTITUTES
      • 3.7.3     BARGAINING POWER OF SUPPLIERS
      • 3.7.4     BARGAINING POWER OF BUYERS
      • 3.7.5     COMPETITIVE RIVALRY
    • 3.8     SUPPLY CHAIN ANALYSIS
    • 3.9     REIMBURSEMENT SCENARIO
      • 3.9.1     REIMBURSEMENT TABLE
    • 3.1     FUNDING SCENARIO
    • 3.11     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.11.1     NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS
      • 3.11.2     SPINAL CORD STIMULATORS GLOBAL MARKET SHARE ANALYSIS
      • 3.11.3     DEEP BRAIN STIMULATORS GLOBAL MARKET SHARE ANALYSIS
      • 3.11.4     SACRAL NERVE STIMULATOR (SNS) GLOBAL MARKET SHARE ANALYSIS
      • 3.11.5     HYPOGLOSSAL NERVE STIMULATOR (HGNS) GLOBAL MARKET SHARE ANALYSIS
    • 3.12     NEUROMODULATION DEVICES NUMBER OF UNITS BASED ON REGION
      • 3.12.1     SPINAL CORD STIMULATION (SCS) NUMBER OF UNITS BASED ON REGION
      • 3.12.2     DEEP BRAIN STIMULATION (DBS) NUMBER OF UNITS BASED ON REGION
      • 3.12.3     SACRAL NERVE STIMULATION (SNS) NUMBER OF UNITS BASED ON REGION
      • 3.12.4     VAGUS NERVE STIMULATION (VNS) NUMBER OF UNITS BASED ON REGION
      • 3.12.5     HYPOGLOSSAL NERVE STIMULATION (HGNS) NUMBER OF UNITS BASED ON REGION
    • 3.13     MARKET PENETRATION
      • 3.13.1     UNITED STATES OBSTRUCTIVE SLEEP APNEA NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
      • 3.13.2     UNITED STATES DRUG RESISTANT EPILEPSY NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
      • 3.13.3     UNITED STATES DEPRESSION NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
      • 3.13.4     UNITED STATES OVERACTIVE BLADDER NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
      • 3.13.5     UNITED STATES CHRONIC PAIN NEUROMODULATION DEVICES MARKET PENETRATION ANALYSIS
      • 3.13.6     BAROREFLEX ACTIVATION THERAPY (BAT) MARKET PENETRATION, PREVALENCE, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED
    • 3.14     NEUROMODULATION DEVICES COMPANY COMPARISON TABLE BASED ON REVENUE, TECHNOLOGY, PRODUCTS AND APPLICATION
  • 4     NEUROMODULATION DEVICES GLOBAL MARKET, BASED ON PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     INVASIVE NEUROMODULATION DEVICES
      • 4.2.1     SPINAL CORD STIMULATION (SCS)
      • 4.2.2     DEEP BRAIN STIMULATION (DBS)
      • 4.2.3     SACRAL NERVE STIMULATION (SNS)
      • 4.2.4     VAGUS NERVE STIMULATION (VNS)
      • 4.2.5     HYPOGLOSSAL NERVE STIMULATION (HGNS)
      • 4.2.6     OTHER INVASIVE NEUROMODULATION DEVICES
        • 4.2.6.1     GASTRIC ELECTRIC STIMULATION (GES)
        • 4.2.6.2     RESPIRATORY ELECTRICAL STIMULATION (RES)/PHRENIC NERVE STIMULATION (PNS)
        • 4.2.6.3     CAROTID SINUS STIMULATION (CSS)
        • 4.2.6.4     RESPONSIVE NEUROSTIMULATION (RNS)
        • 4.2.6.5     REACTIV8 TECHNOLOGY
    • 4.3     NON-INVASIVE NEUROMODULATION DEVICES
      • 4.3.1     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
      • 4.3.2     NEUROMUSCULAR ELECTRICAL STIMULATION (NMES)
      • 4.3.3     OTHER NON-INVASIVE NEUROMODULATION DEVICES
        • 4.3.3.1     TRANSCRANIAL MAGNETIC STIMULATION (TMS)
        • 4.3.3.2     PORTABLE NEUROMODULATION STIMULATION (PONS)
        • 4.3.3.3     TRANSCRANIAL ELECTRICAL STIMULATION (TES)
        • 4.3.3.4     TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
        • 4.3.3.5     TIBIAL NERVE STIMULATION (TNS)
        • 4.3.3.6     TRANSCRANIAL ALTERNATING CURRENT STIMULATION (TACS)
        • 4.3.3.7     TRIGEMINAL NERVE STIMULATION (tNS)
        • 4.3.3.8     PERIPHERAL NERVE STIMULATION (pNS)
        • 4.3.3.9     PERCUTANEOUS ELECTRICAL NERVE STIMULATION (PENS)
        • 4.3.3.10     TRANSCRANIAL ELECTROMAGNETIC TREATMENT (TEMT)
        • 4.3.3.11     VESTIBULAR NERVE STIMULATIO (VENS)
        • 4.3.3.12     PHARYNGEAL ELECTRICAL STIMULATION (PES)
        • 4.3.3.13     NON- INVASIVE VAGUS NERVE STIMULATION (n- VNS)
        • 4.3.3.14     NON- INVASIVE SPINAL CORD STIMULATION
  • 5     NEUROMODULATION DEVICES GLOBAL MARKET, BASED ON APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     PAIN MANAGEMENT
      • 5.2.1     CHRONIC PAIN
      • 5.2.2     FAILED BACK SURGERY SYNDROME (FBSS)
      • 5.2.3     OTHER PAIN MANAGEMENT
    • 5.3     CENTRAL NERVOUS SYSTEM (CNS)
      • 5.3.1     PARKINSON’S DISEASE
      • 5.3.2     DYSTONIA
      • 5.3.3     EPILEPSY
      • 5.3.4     OTHERS
    • 5.4     GASTROENTEROLOGY AND UROLOGY
      • 5.4.1     GASTROPARESIS
      • 5.4.2     URINARY INCONTINENCE
      • 5.4.3     FAECAL INCONTINENCE
    • 5.5     OBSTRUCTIVE SLEEP APNEA (OSA)
    • 5.6     OTHER APPLICATIONS
  • 6     NEUROMODULATION DEVICES GLOBAL MARKET, BASED ON END-USERS
    • 6.1     INTRODUCTION
    • 6.2     HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC)
    • 6.3     CLINICS AND PHYSIOTHERAPY CENTERS
    • 6.4     OTHERS (HOME CARE, ACADEMICS AND RESEARCH INSTITUTES)
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     UNITED STATES (U.S.)
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     UNITED KINGDOM (U.K.)
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     INDIA
      • 7.4.4     REST OF APAC
    • 7.5     REST OF THE WORLD (ROW)
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATIN AMERICA (LATAM)
      • 7.5.3     MIDDLE EAST AND OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     PRODUCT APPROVAL
    • 8.3     PRODUCT LAUNCH
    • 8.4     AGREEMENT AND COLLABORATION
    • 8.5     ACQUISITION
    • 8.6     OTHER DEVELOPMENTS
  • 9     MAJOR COMPANIES
    • 9.1     ABBOTT LABORATORIES
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     AXONICS INC.
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BIOVENTUS (BIONESS INC)
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     BOSTON SCIENTIFIC CORPOARTION
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     INSPIRE MEDICAL SYSTEM, INC.
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     LABORIE MEDICAL TECHNOLOGIES, INC.
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     LIVANOVA PLC
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     MEDTRONIC PLC
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     NEUROPACE, INC.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.1     NEVRO CORPOARTION
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 2     SCS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 3     DBS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 4     SNS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 5     VNS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 6     HGNS NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO’S)
      • TABLE 7     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 8     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 9     INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 10     INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 11     SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 12     DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 13     SACRAL NERVE STIMULATION (SNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 14     VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 16     OTHER INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 17     NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 18     NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 19     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 20     NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 21     OTHER NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 22     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 23     PAIN MANAGEMENT GLOBAL MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 24     PAIN MANAGEMENT GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 25     CHRONIC PAIN GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 26     FAILED BACK SURGERY SYNDROME (FBSS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 27     OTHER PAIN MANAGEMENT GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 28     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 29     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 30     PARKINSON’S DISEASE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 31     DYSTONIA GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 32     EPILEPSY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 33     OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 34     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 35     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 36     GASTROPARESIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 37     URINARY INCONTINENCE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 38     FAECAL INCONTINENCE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 39     OBSTRUCTIVE SLEEP APNEA GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 40     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 41     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 42     HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 43     CLINICS AND PHYSIOTHERAPY CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 44     OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 45     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 46     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 47     NORTH AMERICA INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 48     NORTH AMERICA NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 49     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 50     NORTH AMERICA PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 51     NORTH AMERICA CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 52     NORTH AMERICA GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 53     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 54     NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 55     UNITED STATES NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 56     REST OF NORTH AMERICA NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 57     EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 58     EUROPE INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 59     EUROPE NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 60     EUROPE NEUROMODULATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 61     EUROPE PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 62     EUROPE CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 63     EUROPE GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 64     EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 65     EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 66     GERMANY NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 67     FRANCE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 68     UNITED KINGDOM NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 69     REST OF EUROPE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 70     APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 71     APAC INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 72     APAC NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 73     APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 74     APAC PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 75     APAC CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 76     APAC GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 77     APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 78     APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 79     JAPAN NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 80     CHINA NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 81     INDIA NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 82     REST OF APAC NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 83     ROW NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 84     ROW INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 85     ROW NON-INVASIVE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 86     ROW NEUROMODULATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 87     ROW PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 88     ROW CENTRAL NERVOUS SYSTEM MARKET REVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 89     ROW GASTROENTEROLOGY AND UROLOGY MARKETREVENUE, BASED ON APPLICATION TYPE, (2021-2029) ($MN)
      • TABLE 90     ROW NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 91     ROW NEUROMODULATION DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 92     BRAZIL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 93     REST OF LATAM NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 94     MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2022) ($ MN)
      • TABLE 95     PRODUCT APPROVAL (2020-2022)
      • TABLE 96     PRODUCT LAUNCH (2020-2022)
      • TABLE 97     AGREEMENT AND COLLABORATION (2020-2022)
      • TABLE 98     AGREEMENT AND COLLABORATION (2020-2022)
      • TABLE 99     OTHER DVELOPMENTS (2020-2022)
      • TABLE 100     ABBOTT LABORATORIES.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN)
      • TABLE 101     ABBOTT LABORATORIES.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022)(Q3) ($MN)
      • TABLE 102     ABBOTT LABORATORIES.: TOTAL REVENUE, BASED ON SUB-SEGMENT, (2020-2022)(Q3) ($MN)
      • TABLE 103     ABBOTT LABORATORIES.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q3) ($MN)
      • TABLE 104     AXONICS INC.: TOTAL REVENUE AND R&D EXPENSES (2020-2022 (Q3) ($MN)
      • TABLE 105     AXONICS INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q3) ($MN)
      • TABLE 106     AXONICS INC.: TOTAL REVENUE, BASED ON REGION, (2020-2022 (Q3) ($MN)
      • TABLE 107     BIOVENTUS.: TOTAL REVENUE AND R&D EXPENSES (2020-2022 (Q3) ($MN)
      • TABLE 108     BIOVENTUS.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q3) ($MN)
      • TABLE 109     BIOVENTUS.: TOTAL REVENUE, BASED ON REGION, (2020-2022 (Q3) ($MN)
      • TABLE 110     BOSTON SCIENTIFIC CORPORATION : TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q3) ($MN)
      • TABLE 111     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q3) ($MN)
      • TABLE 112     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON MED SURG SUB - SEGMENT, (2020-2022 (Q3) ($MN)
      • TABLE 113     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-202 (Q3) ($MN)
      • TABLE 114     INSPIRE MEDICAL SYSTEM, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q3) ($MN)
      • TABLE 115     INSPIRE MEDICAL SYSTEM,INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3) ($MN)
      • TABLE 116     LIVANOVA PLC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q3) ($MN)
      • TABLE 117     LIVANOVA PLC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022 (Q3) ($MN)
      • TABLE 118     LIVANOVA PLC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q3) ($MN)
      • TABLE 119     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q2) ($MN)
      • TABLE 120     MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022)(Q2) ($MN)
      • TABLE 121     MEDTRONIC, PLC: NEUROMODULATION TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2022-2022)(Q2) ($MN)
      • TABLE 122     MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2021-2023)(Q2) ($MN)
      • TABLE 123     NEUROPACE, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022 (Q3) ($MN)
      • TABLE 124     NEVRO CORPORATION : TOTAL REVENUE AND R&D EXPENSES (2020-2022 (Q3) ($MN)
      • TABLE 125     NEVRO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022 (Q3) ($MN)

      LIST OF FIGURES

      • FIGURE 1     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: NEUROMODULATION DEVICES GLOBAL MARKET
      • FIGURE 3     NEUROMODULATION DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     NEUROMODULATION DEVICES GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     NEUROMODULATION DEVICES GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     NEUROMODULATION DEVICES GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     NEUROMODULATION DEVICES CLINICAL TRIAL ANALYSIS
      • FIGURE 9     NEUROMODULATION DEVICES CLINICAL TRIAL ANALYSIS
      • FIGURE 10     NEUROMODULATION DEVICES CLINICAL TRIAL ANALYSIS
      • FIGURE 11     NEUROMODULATION DEVICES GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 12     NEUROMODULATION DEVICES: SUPPLY CHAIN ANALYSIS
      • FIGURE 13     NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 14     SPINAL CORD STIMULATOR (SCS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 15     DEEP BRAIN STIMULATOR (DBS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 16     SACRAL NERVE STIMULATOR (SNS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 17     HYPOGLOSSAL NERVE STIMULATOR (HGNS) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 18     UNITED STATES OBSTRUCTIVE SLEEP APNEA NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 19     UNITED STATES DRUG RESISTANT EPILEPSY NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 20     UNITED STATES DEPRESSION NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 21     UNITED STATES OVERACTIVE BLADDER NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 22     UNITED STATES CHRONIC PAIN NEUROMODULATION DEVICES MARKET PENETRATION, 2022 (%)
      • FIGURE 23     U.S. BAT MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2022)
      • FIGURE 24     E.U. COUNTRIES BAT MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2022)
      • FIGURE 25     5 APAC COUNTRIES BAT MARKET PENETRATION, AND OPPORTUNITY, (2022)
      • FIGURE 26     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 27     INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 28     SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 29     DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 30     SACRAL NERVE STIMULATION (SNS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 31     VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 32     HYPOGLOSSAL NERVE STIMULATION (HGNS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 33     OTHER INVASIVE NEUROMODULATION GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 34     NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 V/S 2029) (%)
      • FIGURE 35     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 36     NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 37     OTHER NON-INVASIVE NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON COUNTRY (2022) ($ MN)
      • FIGURE 38     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 39     PAIN MANAGEMENT GLOBAL MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 40     CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET SHARE, BASED ON APPLICATION TYPE, (2022 V/S 2029) (%)
      • FIGURE 41     GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET SHARE, BASED ON APPLICATION TYPE, (2022 V/S 2029) (%)
      • FIGURE 42     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
      • FIGURE 43     NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN), CAGR (%)
      • FIGURE 44     NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BASED ON GEOGRAPHY (2022) (%), COUNTRY ($MN)
      • FIGURE 45     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCTS, (2022 V/S 2029) (%)
      • FIGURE 46     NORTH AMERICA INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 47     NORTH AMERICA NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 48     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 49     NORTH AMERICA PAIN MANAGEMENT MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 50     NORTH AMERICA CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 51     NORTH AMERICA GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 52     NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BASED ON END USER (2022 V/S 2029) (%)
      • FIGURE 53     NORTH AMERICA NEUROMODULATION DEVICES MARKET, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 54     U.S. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 55     U.S. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 56     REST OF NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 57     REST OF NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 58     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
      • FIGURE 59     EUROPE INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 60     EUROPE NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 61     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 62     EUROPE PAIN MANAGEMENT MARKET REVENUE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 63     EUROPE CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 64     EUROPE GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 65     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON END USERS (2022 V/S 2029) (%)
      • FIGURE 66     EUROPE NEUROMODULATION DEVICES MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 67     GERMANY NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 68     GERMANY NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END-USERS (2022 V/S 2029) ($MN)
      • FIGURE 69     FRANCE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 70     FRANCE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 71     U.K. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029)($MN)
      • FIGURE 72     U.K. NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 73     REST OF EUROPE NEUROMODULATION DEVICES MARKET REVENUE,BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 74     REST OF EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) (%)
      • FIGURE 75     APAC NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
      • FIGURE 76     APAC INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 77     APAC NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 78     APAC NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 79     APAC PAIN MANAGEMENT MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 80     APAC CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 81     APAC GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 82     APAC GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON END USERS (2022 V/S 2029) (%)
      • FIGURE 83     APAC NEUROMODULATION DEVICES MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 84     JAPAN NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 85     JAPAN NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
      • FIGURE 86     CHINA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 87     CHINA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 88     INDIA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 89     INDIA NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 90     REST OF APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 91     REST OF APAC NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
      • FIGURE 92     ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 93     ROW INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 94     ROW NON-INVASIVE NEUROMODULATION DEVICES MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 95     ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 96     ROW PAIN MANAGEMENT MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 97     ROW CENTRAL NERVOUS SYSTEM MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 98     ROW GASTROENTEROLOGY/UROLOGY MARKET SHARE, BASED ON APPLICATION TYPE (2022 V/S 2029) (%)
      • FIGURE 99     ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON END USER (2022 V/S 2029) (%)
      • FIGURE 100     ROW NEUROMODULATION DEVICES MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 101     BRAZIL NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCTS AND APPLICATIONS (2022 V/S 2029) ($MN)
      • FIGURE 102     BRAZIL NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USERS (2022 V/S 2029) ($MN)
      • FIGURE 103     REST OF LATAM NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 104     REST OF LATAM NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
      • FIGURE 105     MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 106     MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES MARKET REVENUE, BASED ON END USER (2022 V/S 2029) ($MN)
      • FIGURE 107     KEY GROWTH STRATEGIES, (2020-2022)
      • FIGURE 108     SWOT: ABBOTT LABORATORIES
      • FIGURE 109     SWOT: AXONICS INC.
      • FIGURE 110     SWOT: BIOVENTUS
      • FIGURE 111     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 112     SWOT: INSPIRE MEDICAL SYSTEM, INC.
      • FIGURE 113     SWOT: LABORIE MEDICAL TECHNOLOGY INC.
      • FIGURE 114     SWOT: LIVANOVA PLC
      • FIGURE 115     SWOT: MEDTRONIC PLC.
      • FIGURE 116     SWOT: NEUROPACE, INC.
      • FIGURE 117     SWOT: NEVRO CORPORATION

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     Abbott Laboratories
      • 2     Atrotech Oy
      • 3     Avery Biomedical Devices Inc.
      • 4     AxioBionics
      • 5     Axonics Inc.
      • 6     Beijing Pins Medical Co., Ltd.
      • 7     Beurer GMBH
      • 8     Bioventus Inc (Bioness, Inc.)
      • 9     BioWave Corporation
      • 10     Bluewind Medical
      • 11     Boston Scientific
      • 12     Brainsway
      • 13     Cala Health
      • 14     Cefaly Technology
      • 15     CVRx, Inc.
      • 16     Cymedica Orthopedics
      • 17     DyAnsys
      • 18     EB Neuro S.P.A.
      • 19     electroCore
      • 20     eNeura Inc
      • 21     Fysiomed B.V.
      • 22     Gimer Medical
      • 23     Inspire Medical Systems, Inc
      • 24     Laborie Medical System Inc
      • 25     Livanova Plc
      • 26     Magnus Medical
      • 27     Magstim TMS
      • 28     Magventure A/S
      • 29     Mainstay Medical
      • 30     Medtronic Plc
      • 31     NeurAxis
      • 32     Neurocare Group Gmbh
      • 33     Neuroelectrics
      • 34     Neurolief Ltd
      • 35     NeuroMetrix
      • 36     Neuronetics
      • 37     Neuropace Inc
      • 38     Neurosigma Inc.
      • 39     Neurovalens
      • 40     Nevro Corporation
      • 41     Nexstim Plc
      • 42     Nyxoah SA
      • 43     Phagenesis
      • 44     Precisis AG